Liver Cancer: Effects, Safety, and Cost-effectiveness of Controlled-Release Oxycodone for Pain Control after TACE

Zhou, Bo; Wang, Jianhua; Yan, Zhiping; Shi, Peng; Kan, Zuxing

doi:10.1148/radiol.11110552

Cited by 21 publications

(16 citation statements)

References 27 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This was consistent with the part result of Ise et al' study (Ise et al, 2009;Wiffen et al, 2014). And other studies showed that there was no abundant evidence to prove which is better ( Fredheim et al, 2010;Zhou et al, 2012).…”

Section: Discussionsupporting

confidence: 87%

Pharmacoeconomics Evaluation of Morphine, MS Contin and Oxycodone in the Treatment of Cancer Pain

Zhang

Yang²,

Zhao³

2014

Asian Pacific Journal of Cancer Prevention

View full text Add to dashboard Cite

Objective: To analyze cost-effectiveness of morphine, MS contin and oxycodone in the treatment of cancer pain, providing guidance for rational drug use in the clinic. Methods: Confirmed by histology, a total of 171 patients with various cancers who required analgesic treatment were selected and divided into 3 groups, 57 cases for each group, given morphine, MS contin and oxycodone, respectively. If there appeared a poor short-term effect or aggravated sudden pain during the treatment, a short-acting morphine injection was given and adverse reactions were processed by symptomatic treatment. The pain relief rate and adverse reactions of groups were observed and pharmacoeconomics evaluation was undertaken.

show abstract

Section: Discussionsupporting

confidence: 87%

Pharmacoeconomics Evaluation of Morphine, MS Contin and Oxycodone in the Treatment of Cancer Pain

Zhang

Yang²,

Zhao³

2014

Asian Pacific Journal of Cancer Prevention

View full text Add to dashboard Cite

show abstract

“…PCA pumps provide good analgesic effects that alleviate postoperative acute pain; however, they may cause adverse reactions, including respiratory depression, nausea and vomiting, sleepiness, cutaneous pruritus and hepatic dysfunction. 9,10 The results of the present study demonstrated that, compared with a control group, NRS scores in PCA patients gradually decreased over time, confirming the evident analgesic effects of PCA pumps. However, the incidence of postoperative adverse reactions, including nausea and vomiting, cutaneous pruritus, respiratory depression, sleepiness and hepatic dysfunction were significantly higher in PCA patients compared with the control group, indicating the potential risks of using a PCA pump as postoperative analgesic.…”

Section: Discussionsupporting

confidence: 76%

Postoperative local incision analgesia for acute pain treatment in patients with hepatocellular carcinoma

et al. 2018

Rev. Assoc. Med. Bras.

View full text Add to dashboard Cite

Objective: The present study aimed to investigate the analgesic effect and safety of using local incision analgesia to treat acute postoperative pain in patients with hepatocellular carcinoma (HCC). Method: A cohort of 60 patients undergoing liver cancer resection was randomly divided into three groups (n=20 per group): local incision analgesia (LIA) group, which received local infiltration with ropivacaine combined with a postoperative analgesia pump; intravenous patient-controlled analgesia (PCA) group, which received fentanyl intravenous analgesia postoperatively; and the control group, which received tramadol hydrochloride injection postoperatively according to the NRS scoring system. The postoperative analgesic effect in each group was compared and tumor recurrence (survival) was analyzed using the Kaplan-Meier method. Results: NRS scores, rate of analgesic usage, ambulation time (h) and intestinal function recovery time (h) were significantly reduced in LIA group compared with the control group at each postoperative time point (6, 12, 24 and 48 hours; p<0.05). Additionally, the NRS scores of LIA patients at 12 hours post-surgery was significantly reduced compared with PCA group (p<0.05), and the occurrence of postoperative adverse events in LIA group was significantly lower than that in PCA group (p<0.05). Survival analysis demonstrated that the mean survival time (tumor recurrence) was significantly increased in LIA group compared with the control group (χ 2 =4.749; p=0.029). Conclusion: Local incision analgesia improves the analgesic effect, causes fewer adverse reactions and increases postoperative survival time. Our study demonstrated that local incision analgesia is a safe and effective method of postoperative pain management following hepatectomy.

show abstract

“…23 Studies using PO oxycodone 8,24 after TACE reported an adequate analgesic effect, as defined within these studies. The only available placebo-controlled randomized controlled trial (RCT) 24 reported superior pain control in groups receiving PO controlledrelease oxycodone (CRO). The intervention groups also demonstrated lower pain scores but an increased incidence of mild to moderate RUQP and a shorter LoS.…”

Section: Intravenous or Oral Analgesiamentioning

confidence: 99%

“…The analgesics used were IV morphine 8,15,17 and PO oxycodone 8,24 (PO morphine sulfate was used as a control). 23 Studies using PO oxycodone 8,24 after TACE reported an adequate analgesic effect, as defined within these studies. The only available placebo-controlled randomized controlled trial (RCT) 24 reported superior pain control in groups receiving PO controlledrelease oxycodone (CRO).…”

Section: Intravenous or Oral Analgesiamentioning

confidence: 99%

Management of Postembolization Syndrome Following Hepatic Transarterial Chemoembolization for Primary or Metastatic Liver Cancer

Blackburn¹,

West²

2016

Cancer Nurs

View full text Add to dashboard Cite

show abstract

Liver Cancer: Effects, Safety, and Cost-effectiveness of Controlled-Release Oxycodone for Pain Control after TACE

Abstract: CRO is effective, safe, and cost-effective in the control of postoperative pain after transarterial chemoembolization for patients with inoperable liver cancer.

Cited by 21 publications

References 27 publications

Pharmacoeconomics Evaluation of Morphine, MS Contin and Oxycodone in the Treatment of Cancer Pain

Pharmacoeconomics Evaluation of Morphine, MS Contin and Oxycodone in the Treatment of Cancer Pain

Postoperative local incision analgesia for acute pain treatment in patients with hepatocellular carcinoma

Management of Postembolization Syndrome Following Hepatic Transarterial Chemoembolization for Primary or Metastatic Liver Cancer

Contact Info

Product

Resources

About